东阳光(600673.SH):东阳光药拟放弃公司控股股东下属药物研发业务板块的相关研发成果的优先购买权
格隆汇 3 月 19日丨东阳光(600673.SH)公布,根据公司控股股东关于避免同业竞争的承诺,公司控股子公司东阳光药拥有公司控股股东及公司实际控制人下属药物研发业务板块的研发成果的优先购买权。近日,公司收到控股股东的通知,其控股子公司广东东阳光药为聚焦于抗感染、抗肿瘤、代谢领域的核心产品线项目的研发,计划以包括但不限于独占许可等方式将其具有独立知识产权的可溶性鸟苷酸环化酶刺激剂、盐皮质激素受体拮抗剂、法尼醇X受体激动剂、低氧诱导因子-脯氨酰羟化酶抑制剂、5-HT再摄取抑制剂和5-HT1A受体部分激动剂、FLT3高选择性抑制剂、Axl和Mer双靶点小分子酪氨酸激酶抑制剂等7个在研项目的研发及商业化权利进行对外授予,许可费用总额预计为10至15亿元人民币,并询问东阳光药是否行使优先购买权。考虑到拟许可项目目前均处于临床前研究阶段至临床I期阶段内,项目研发周期较长,预计研发投入大,研发风险较高,且拟许可项目与东阳光药的适应症领域配置、产品管线布局及未来发展规划关联性不大,如收购该项目产品后续还需要投入大量时间和资金建设、完善相关适应症领域的生产车间和商业推广团队,整体成本投入大而收益回报不确定,因此东阳光药拟放弃该项目的优先购买权。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.